Ezra Klein’s podcast reveals that one in eight American adults now use GLP‑1 drugs, a figure that surprised both hosts. The surge stems from diabetes treatment, weight‑loss demand and aggressive online marketing that exploded after Covid‑19 telemedicine took off. Julia Belluz, a health reporter, breaks down why the medication, originally a diabetes therapy, has become a mainstream appetite suppressant.

Belluz explains that GLP‑1s mimic a gut hormone that tells the brain to feel full, effectively dialing down hunger. Trials showed users shed 15‑22% of body weight, rivaling bariatric surgery, while also improving heart, kidney and liver markers. The newer formulation, Zepbound, builds on the first‑generation Ozempic and Wegovy, extending the drug’s reach into brain pathways that signal toxicity, which produces nausea as a common side effect.

Investors watch the “Ozempic era” closely; demand fuels a booming market for injectable weight‑loss drugs and spurs competition among pharma firms. As patients adopt these hormones for both disease management and elective weight loss, insurers and regulators face pressure to define appropriate use, while the broader cultural shift toward chemically engineered appetite control reshapes consumer expectations about food and health.